OMGA - Omega rises as H.C. Wainwright initiates with Buy citing potential in epigenetics

• Omega Therapeutics ( NASDAQ: OMGA ) recovered from four days of consecutive declines on Thursday after H.C. Wainwright launched its coverage with a Buy recommendation noting that the clinical-stage biotech is a pioneer in epigenetic medicines.
• Omega's ( OMGA ) epigenomic programming platform leverages epigenetics, which controls gene expression and regulates an organism's life from cell genesis, growth, and differentiation to cell death.
• While classified as mRNA molecules, the company's therapeutic candidates are "modularly designed to regulate gene expression to address hitherto undruggable targets," the analyst Robert Burns wrote, with a 12-month target of $11 on the stock.
• Additionally, the analyst notes that the company uses artificial intelligence and machine learning to speed up drug development, with its lead candidate OTX-2002 reaching the clinical from the initial validation in 27 months compared to the typical 3–4-year timeline.
• In November, Omega ( OMGA ) announced that the FDA issued its orphan drug designation for OTX-2002 to treat liver cancer hepatocellular carcinoma (HCC).

For further details see: